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A B S T R A C T
Purpose
We sought to define the prevalence and co-occurrence of actionable genomic alterations in
patients with high-grade bladder cancer to serve as a platform for therapeutic drug discovery.
Patients and Methods
An integrative analysis of 97 high-grade bladder tumors was conducted to identify actionable drug
targets, which are defined as genomic alterations that have been clinically validated in another
cancer type (eg, BRAF mutation) or alterations for which a selective inhibitor of the target or
pathway is under clinical investigation. DNA copy number alterations (CNAs) were defined by
using array comparative genomic hybridization. Mutation profiling was performed by using both
mass spectroscopy-based genotyping and Sanger sequencing.
Results
Sixty-one percent of tumors harbored potentially actionable genomic alterations. A core
pathway analysis of the integrated data set revealed a nonoverlapping pattern of mutations in
the RTK-RAS-RAF and phosphoinositide 3-kinase/AKT/mammalian target of rapamycin path-
ways and regulators of G1-S cell cycle progression. Unsupervised clustering of CNAs defined
two distinct classes of bladder tumors that differed in the degree of their CNA burden.
Integration of mutation and copy number analyses revealed that mutations in TP53 and RB1
were significantly more common in tumors with a high CNA burden (P  .001 and P 
.003, respectively).
Conclusion
High-grade bladder cancer possesses substantial genomic heterogeneity. The majority of tumors
harbor potentially tractable genomic alterations that may predict for response to target-selective
agents. Given the genomic diversity of bladder cancers, optimal development of target-specific
agents will require pretreatment genomic characterization.
J Clin Oncol 31:3133-3140. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Approximately 70,000 cases of bladder cancer are
diagnosed annually in the United States with more
than 14,000 disease-related deaths.1 In the meta-
static setting, bladder cancer is almost always incur-
able and no systemic therapy has been shown to
prolong survival in patients who have progressed
following first-line cisplatin-based chemotherapy.
Novel approaches are thus urgently needed for this
common, highly lethal malignancy.
The realization that tumors are dependent on
driver mutations that promote and maintain the
malignant phenotype, even when in an advanced
state, has led to dramatic improvements in antican-
cer therapy. Increasingly, cancers are classified by
the ensemble of mutant genes they harbor; targeting
such genes with selective inhibitors has resulted in
profound clinical impact in lung adenocarcinomas
with EGFR mutations or EML4-ALK rearrange-
ments, BRAF-mutant melanomas, and in several
additional genetically defined solid tumors.2-5 The
extent, duration, and rates of response for many of
these examples are unprecedented and have led to
rapid drug approval in molecularly defined pa-
tient subsets.
With the goal of accelerating the adoption of a
precision medicine-based approach for patients
with advanced bladder cancer, we performed an in-
tegrated genomic analysis to define the prevalence
and patterns of co-occurrence of therapeutically
tractable genomic alterations in 97 high-grade
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urothelial tumors. We identified discrete subsets of bladder cancers
defined by the presence of actionable alterations in the mitogen-
activated protein kinase (MAPK) and phosphoinositide 3-kinase
(PI3K)/AKT pathways as well as regulators of G1-S phase cell cycle
progression. Our findings indicate that although bladder cancer, as
defined by site of origin, is genetically heterogeneous, therapies target-
ing specific alterations may prove effective if patients with appropriate
molecular profile are identified prospectively.
PATIENTS AND METHODS
Mutation Detection
All tumor samples and associated clinical data were collected retrospec-
tively under a protocol approved by the institutional review board or waiver of
authorization. Tumors were snap-frozen at resection. A reference cryostat
section stained with hematoxylin and eosin was reviewed for every sample by a
board-certified genitourinary pathologist (H.A.-A.), and samples were mac-
rodissected to ensure  60% tumor content. Mutation analysis was performed
by using both mass spectrometry–based genotyping and Sanger sequencing as
previously described.6,7
DNA Copy Number Profiling
Labeled tumor DNA was cohybridized to Agilent 1 M human oligonu-
cleotide comparative genomic hybridization microarrays with commercially
available reference normal DNA (Roche, Basel, Switzerland). Raw copy num-
ber estimates were normalized, segmented by using circular binary segmenta-
tion, and analyzed by using the RAE algorithm as previously described.8
Regions with false discovery rates less than 1% were considered significant;
regions of statistically significant genomic alterations were excluded if they
were known or presumed germline copy number polymorphisms or if they
overlapped with previously identified variants. All genome coordinates
were based on the National Center for Biotechnology Information build
36.1 (hg18) of the reference human genome.
RNA Expression Profiling
Total RNA was extracted by using the RNeasy kit (Qiagen, German-
town, MD), labeled (TotalPrep RNA Labeling Kit; Ambion, Carlsbad, CA),
and hybridized to Human HT-12 Expression BeadChip arrays (Illumina,
San Diego, CA). Arrays were scanned on a BeadArray Reader (Illumina),
and gene-level messenger RNA data were normalized by using quantile
normalization.9 The E2F3 expression signature score was calculated by
summing the expression scores for a panel of genes regulated by the
E2F3 transcription factor.
Drug Sensitivity Testing
Cell lines underwent DNA fingerprinting to exclude the possibility of
mislabeling or cross-contamination.6 Cell viability was assayed via trypan blue
exclusion. Immunoblot analysis was performed to assess the effect of MK2206
(2.5 mol/L) treatment on downstream PI3K/AKT pathway intermediates.
Statistical Analysis
Overall survival (OS) was defined as time from date of surgery to death as
a result of any cause, and time to recurrence was defined as time from surgery
to recurrence with pathologic confirmation or, if not present, with Response
Evaluation Criteria in Solid Tumors (RECIST)–based radiographic confirma-
tion. Association of specific copy number alterations (CNAs) with time to
recurrence and OS was tested by using the log-rank test and univariate Cox
proportional hazards regression. OS between tumor cohorts was compared by
using stratified Cox regression. Cancer-specific survival was compared by
using a competing risk model. For disease-specific survival analysis, deaths
from other and unknown causes were combined and treated as competing
events. Competing risk analysis was performed using the “cmprsk” R
package. Associations between binary variables (eg CNA status [high v
low], stage [I to II v III to IV]), treatment with neoadjuvant chemotherapy,
and point mutations and CNAs were tested by using Fisher’s exact test.
Wilcoxon rank sum testing was used to compare the total number of
alterations with clinical parameters.
Data Availability
Data are publically available through the Memorial Sloan-Kettering
Cancer Center (MSKCC) cBioPortal for Cancer Genomics.10,10a
RESULTS
We performed an integrated analysis of 97 high-grade urothelial tu-
mors (Table 1). Patients with these tumors carry a substantial risk for
recurrence and subsequent disease-specific mortality. Fifty-seven tu-
mors (59%) were histopathologically classified as transitional cell
carcinoma not otherwise specified. Thirty patients (31%) had pre-
dominantly transitional cell carcinoma with additional minor histo-
logic components (Data Supplement). Ten samples (10%) displayed
predominantly neuroendocrine features.
To confirm that this cohort was representative of patients with
bladder cancer who were treated at our institution, we identified a
contemporary comparator cohort of 285 consecutively treated age-,
sex-, and stage-matched patients (in a 3:1 ratio). Patients in this com-
parator cohort had undergone radical cystectomy for bladder cancer
at MSKCC between 2007 and 2010. The frequency of histologic sub-
types between cohorts was comparable with the exception of neuroen-
docrine tumors, which were not present in the comparator cohort.
The median OS times for the comparator and study cohorts were 38
and 35.2 months, respectively (P  .19; Data Supplement), with
similar cancer-specific survivals (P  .61).
To define the landscape of CNAs in high-grade bladder cancers,
we performed high-resolution array comparative genomic hybridiza-
tion. Unsupervised clustering of segmented copy number events re-
vealed two distinct tumor subsets differing in their degree of CNA
burden (high-burden v low-burden CNA; Fig 1A). Tumor content, as
estimated by pathologic review, was similar between the low-burden
and high-burden CNA clusters, indicating that differences in the ex-
tent of copy number events between clusters could not be attributed to
Table 1. Select Clinical Characteristics of 97 High-Grade Urothelial
Carcinoma Samples











Surgical stage (95 tumors)





Neoadjuvant chemotherapy 34 35
Abbreviation: TURBT, transurethral resection of bladder.
Iyer et al
3134 © 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
A
B
















Head and neck squamous cell carcinoma
Breast
Nonhypermutated







(this study, n = 97) Low-burden CNA
High-burden CNA
0.0 0.1 0.2 0.3 0.4 0.5










































Fig 1. Landscape of DNA copy number alterations (CNAs) in high-grade bladder cancer. (A) Unsupervised hierarchical clustering of array comparative genomic hybridization data
identified two distinct classes of bladder cancers. TP53 and RB1 alterations were significantly more common in the high copy number aberrant subset. (B) Fraction of the genome
altered in the subsets of bladder tumors with high and low copy number aberrations and in additional select human cancers. The cohort of copy number data used for comparison
was derived from multiple large tumor collections analyzed by array comparative genomic hybridization (both published and unpublished data) and includes The Cancer Genome Atlas
tumor types with more than 100 available samples. It represents a composite, unbiased data set for comparing global copy number changes across myriad tumor subtypes (see Data
Supplement for list of references from which these data were derived). (C) Statistically significant genomic amplifications (red) and deletions (blue) inferred from RAE analysis are
indicated across the autosomes. Select genes located within recurrently amplified or deleted regions are highlighted.
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differences in stromal contamination. We compared the CNA burden
of the study cohort to 5,135 tumors from 14 diverse nonhematologic
tumor types (Fig 1B). Only serous ovarian cancers demonstrated a
greater degree of mean structural aberration than the high-burden
CNA bladder tumors. In contrast, the degree of structural aberration
in the low-burden CNA bladder cancers was similar to hypermutated
uterine endometrioid and prostate cancers and greater only than
hypermutated colorectal cancers. Although two subsets of genetically
distinct tumors could be defined by CNA burden, these did not define
clinically distinct disease subsets. Specifically, there was no significant
difference in the rate of recurrence-free, OS, or cancer-specific survival
between the two groups (P  .98, P  .75, and P  .49, respectively),
with both demonstrating a high bladder cancer–specific mortality
(Data Supplement).
To identify recurrent, functionally significant CNAs that may
represent driver events, we used the statistical method RAE (Fig 1C;
Data Supplement). Notable regions of amplification included 11q13.2
to 13.3 spanning the CCND1 gene and the 17q12 locus encoding the
ERBB2 gene. The most commonly deleted locus was 9p21.3 spanning
the CDKN2A and CDKN2B tumor suppressor genes. The most fre-
quent arm-length gains and losses were 20q (41.2%) and 11p (36.1%),
respectively. These results are consistent with the results of previous
array-based studies that identified partial or complete loss of chromo-
some 9 as well as 20q and 17q21 gain as common events in blad-
der cancer.11-13
Because alterations in gene copy number represent only one
mechanism of oncoprotein dysregulation, we performed mutation
profiling of all 97 tumors. Using a mass spectrometry–based Seque-
nom iPLEX assay, we detected hotspot alterations in select cancer
genes.6,7 Sanger sequencing of all coding exons of 15 oncogenes and
tumor suppressor genes, selected for their potential as predictive bio-
markers of response to targeted agents, was also performed (Data
Supplement). Sixty-three samples (65%) harbored mutations in at
least one gene, the most prevalent of which were TP53 (34%), FGFR3
(13%), and PIK3CA (18%). Integration of mutation and copy num-
ber data revealed that TP53 and RB1 alterations were significantly
more common in high-burden CNA tumors (P  .001 and P  .003,
respectively; Fig 1A). Correlations between survival, stage, neoadju-
vant chemotherapy, and select aberrations are described in the
Data Supplement.
To better define the co-occurrence pattern of mutations and
CNAs, we grouped genes into core signal transduction pathways or
canonical cell functions. MAPK pathway alterations were identified in
35% of samples (Fig 2A). The most commonly altered genes were
FGFR1, FGFR3, ERBB2, MET, NF1, KRAS, and BRAF, each occurring
in 2% to 13% of patients and arising in a predominantly mutually
exclusive pattern, suggesting that these events confer overlapping phe-
notypic effects. Because ERBB2 amplification is a validated drug target
in breast and esophogastric tumors,14-16 we further explored the sig-
nificance of the ERBB2 amplifications (six patients [6.2%]) in our
tumor cohort. Focal ERBB2-amplified tumors were found to exhibit
increased ERBB2 messenger RNA expression as compared with
nonamplified samples and 3 HER2 protein overexpression by im-
munohistochemistry (Figs 2B and 2C).
Consistent with studies of other solid tumors,17,18 TP53 muta-
tion and MDM2 (which encodes an E3 ubiquitin ligase for p53)
amplification occurred in a nonoverlapping distribution (Fig 3A).
Alteration in genes that regulate G1-S phase transition were also highly
prevalent (60% of all tumors analyzed; Fig 3B). Specifically, mutually
exclusive focal amplifications of CCND1 and CCNE1 were present in
14% and 5% of samples, respectively, and were inversely correlated
with the presence of RB1 mutations or deletions. A similar pattern of
mutual exclusivity was not observed among these three genes and
E2F3 amplification (21%) or CDKN2A deletion or mutation (24%).
Amplification of the E2F3 locus was notable, because amplifica-
tion of this region rarely occurs in other epithelial tumor types (21% v
4.9% of 1,932 nonurothelial epithelial tumors) and was associated
with more advanced stage (28% stage III to IV v 6.7% stage I to II;
P  .028).19 Thus, E2F3 amplification may represent a lineage-specific
event in bladder cancer, similar to MITF amplification in metastatic
melanoma. To assess the functional impact of E2F3 amplifications in
bladder cancer, we calculated an E2F3 activity score from the expres-
sion levels of 23 experimentally validated E2F3 target genes20 (Data
Supplement). Tumor samples with E2F3 amplifications or RB1 mu-
tations or homozygous deletions exhibited high E2F3 signature scores
(Fig 3B). Samples with CCND1 or CCNE1 amplification had, on
average, lower E2F3 signature scores, whereas tumors with either
CDKN2A alterations or those lacking alterations in all five genes ex-
hibited the lowest scores. Nevertheless, the latter group of wild-type
tumors expressed the E2F3 signature heterogeneously, suggesting the
presence of occult alterations that phenocopy the effects of E2F3
amplification and/or RB1 inactivation in some E2F3/RB1–wild-type
bladder tumors. Expression profiling data indicated a strong concor-
dance between copy number aberration and expression score for all
genes except RB1 (Data Supplement).
Because RB1 alterations are found in the majority of neuroendo-
crine lung cancers,21 we correlated RB1 and E2F3 alterations with the
presence of neuroendocrine histology. Both E2F3 amplification and
RB1 deletion/mutation were more prevalent in the subset of tumors
exhibiting neuroendocrine differentiation compared with those with
predominantly urothelial morphology (E2F3, 50% v 17%; P  .03;
RB1, 50% v 13%; P  .01). Tumors containing neuroendocrine mor-
phology also had higher rates of TP53 alterations and a higher CNA
burden (Data Supplement).
Collectively, our integrated analysis revealed that although blad-
der cancers are genetically heterogeneous, subsets of tumors could be
identified by discrete, nonoverlapping alterations that could serve as
the basis for therapeutic intervention. Notably, 61% of tumors har-
bored an actionable alteration (events that, on the basis of clinical or
preclinical data, would be predicted to confer sensitivity to selective
inhibitors approved for use in other malignancies or currently in
clinical testing). To determine whether the genomic heterogeneity of
the human disease could be modeled in preclinical studies, we per-
formed a similar integrative analysis on a panel of bladder cancer cell
lines. We found only a modest overlap between the genomic profile of
the tumor and cell line cohorts. For example, none of the bladder
cancer cell lines had focal amplification of the ERBB2 gene. Neverthe-
less, several potentially actionable alterations were observed in both
the tumor and cell line panels. In particular, aberrations in genes
within the PI3K/AKT signaling pathway were highly prevalent in both
(Fig 4A; Data Supplement).
To explore the functional significance of PI3K/AKT alterations in
bladder cancer, we assessed the AKT dependence of a subset of the
bladder cancer cell lines as a function of their pathway mutation status
by using MK2206, a highly selective, allosteric inhibitor of AKT1,
AKT2, and AKT3. We chose this drug for its therapeutic relevance,
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since it is currently being investigated in multiple solid tumor malig-
nancies. Cell lines harboring PIK3CA and AKT1 mutations were
highly sensitive to MK2206, those with alterations in upstream path-
way components including FGFR-3 and HRAS less so, whereas cell
lines with downstream TSC-1 alterations were resistant to AKT inhi-
bition (Fig 4B). In bladder cancer cells with PIK3CA mutations, treat-
ment with MK2206 resulted in downregulation of phosphorylated
AKT and inhibition of downstream AKT effectors including FOX-01/
03, PRAS40, S6, and 4EBP (Fig 4C). Treatment of TSC-1–null bladder
cancer cells with MK2206 similarly resulted in potent inhibition of
AKT activation and proximal AKT effectors, including phospho–
FOX-01/03 and phospho-PRAS40, but in contrast to the effects of
AKT inhibition in PIK3CA-mutant cells, a significant reduction in
phosphorylated S6 and 4EBP1 expression was not observed.
Therefore, although PI3K/AKT/mammalian target of rapamycin
(mTOR) pathway mutations are common in bladder cancer, the
sensitivity of bladder tumors to selective inhibitors of this pathway
will be dictated by the underlying genetic determinant of path-
way activation.
DISCUSSION
This integrative genomic analysis was performed to define the preva-
lence and co-occurrence of actionable drug targets in patients with
high-grade bladder cancer. Sixty-one percent of tumors harbored
potentially actionable alterations, including clinically validated drug
targets such as focal, high-level ERBB2 amplification16 and BRAF and
TSC1 mutations.5,22,23 A large proportion of tumors also harbored
mutations and/or gene amplifications for which targeted inhibitors
are currently in advanced clinical testing, including FGFR3 and
PIK3CA mutations, PTEN deletions, and FGFR1, CCND1, and
MDM2 amplifications.7,24-26 The largely nonoverlapping distribu-
tion of abnormalities in potentially actionable genes revealed by
our core pathway analysis suggests that these alterations likely
represent driver events and should be evaluated as drug targets in
this disease. The Data Supplement lists select alterations found in
our study cohort for which targeted therapies are currently avail-
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Fig 2. Co-occurrence of alterations within the RTK/RAS/RAF signaling pathway in high-grade bladder cancer. (A) Incidence (%) of amplifications, deletions, and
mutations of select receptor tyrosine kinases and downstream targets. The heatmap compares the distribution of each alteration across tumor samples (bottom).
(B) ERBB2-amplified samples are highlighted (left), and ERBB2 transcript expression levels as a function of ERBB2 gene copy number are indicated (right).
ERBB2-amplified samples also exhibited significantly increased messenger RNA (mRNA) expression levels as compared with diploid samples. (C)
Immunohistochemistry analysis of a representative ERBB2-amplified tumor sample exhibiting 3 human epidermal growth factor receptor 2 (HER2)
overexpression and an ERBB2-nonamplified tumor sample shown for comparison (right). Ampl., amplified; H&E, hematoxylin and eosin; Hetloss, heterozygous
loss.
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Our integrated analysis revealed that bladder cancer is a genetically
heterogeneous disease with no single pathognomonic molecular event.
Tumors could be divided into two discrete subsets (high- or low-
burden CNAs) and the degree of CNA correlated with the presence of
TP53 and/or RB1 abnormalities. This result is consistent with prior
studies showing that TP53 and RB1 inactivation induces genomic
instability and promotes aneuploidy.27,28 Although not clinically
distinct, the strong correlation between the degree of structural
aberration and TP53 and RB1 mutation status suggests that these
events play a central role in the pathogenesis of high-burden CNA
bladder cancers.
Because functional studies using human cancer cell lines have
historically served as the basis for the clinical development of novel
cancer therapies, we compared the genomic profile of the high-grade
bladder cancers to a collection of bladder cancer cell lines commonly
used in preclinical studies. We found only a modest overlap between
the genomic profiles of the tumors and cell lines with some potential
drug targets, such as ERBB2 amplification, not represented in the cell
lines. These results indicate that a significantly larger panel of bladder
cancer cell lines will be needed to model the genomic complexity of
this disease. Because genomic alterations in the PI3K/AKT/mTOR
pathway were common in both, a subset of cell lines was used to
determine whether mutation status predicted for sensitivity to the
selective AKT inhibitor MK2206. Consistent with data from breast
and ovarian cancers,24,29 treatment of PIK3CA- and PTEN-mutant
cell lines with MK2206 was associated with modulation of AKT, its
downstream effectors, and cell proliferation. In contrast, cell lines with
mutations in TSC-1, a downstream effector of the PI3K/AKT path-
way, were resistant to MK2206 despite potent inhibition of AKT and
the proximal AKT substrates PRAS40 and FOX-01/03. AKT effectors
downstream of TSC1, including S6 and 4EBP1, were not inhibited by
MK2206 in TSC1 null cells, a result analogous to the resistance of
KRAS-mutant cells to EGFR-directed therapies.30,31 These results sug-
gest that response to selective inhibitors of kinase signaling pathways
in bladder cancer may vary as a function of the molecular basis of
pathway activation.
There were several limitations inherent to the sample set analyzed
in this study. The inclusion of tumors with predominantly neuroen-
docrine histology in the study cohort may have influenced the preva-
lence of some genetic aberrations: neuroendocrine tumors were more
likely to harbor alterations in TP53, RB1, and E2F3. Furthermore, it is










































































Fig 3. Alterations within the TP53 and RB1/E2F3 pathways in high-grade bladder cancer. (A) Heatmap showing the distribution of TP53 and MDM2 alterations. (B)
The RB1 cell cycle regulatory pathway with incidence of mutations and copy number alterations displayed for each gene along with a heatmap showing the
co-occurrence of genetic alterations in this pathway. The boxplot (right) depicts the association between an E2F3 expression signature score and alterations within
genes involved in the RB1 pathway (“multiple” refers to more than one gene in this pathway altered in the same tumor sample). Those samples harboring E2F3
amplification or amplification of multiple genes within the RB1 pathway display significantly increased E2F3 activity scores compared with tumors lacking amplification
of any component of the pathway (labeled as “none”). P values were calculated by t test.
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between primary and metastatic tumors. An analysis of matched pri-
mary and metastatic samples from the same patient would address this
possibility and should be a focus of future research efforts. Finally,
several reports in other tumor types have illustrated the potential
impact of intratumoral heterogeneity on the efficacy of targeted
agents.32 Approximately one third of the tumors in this study exhib-
ited minor histologic components such as squamous or sarcomatoid
differentiation, a result similar to a historical series at our institution in
which 27% of tumors evinced divergent differentiation (unpublished
data). Emerging next-generation methodologies may allow for a de-
termination of whether such intratumoral histologic heterogeneity
reflects intratumoral genomic heterogeneity and/or polyclonality.
In conclusion, we find that approximately 60% of bladder can-
cers harbor potentially actionable genetic alterations that have either
been validated as drug targets in other solid tumors or for which
selective inhibitors are currently in early clinical testing. Bladder can-
cers, however, exhibit significant genetic heterogeneity, with most
potentially actionable alterations identified in a minority of patients.
Therefore, an effective drug for which activity is restricted to a molec-
ularly defined bladder cancer subtype would likely be deemed clini-
cally inactive if tested in a nonenriched patient population. Our results
suggest that the failure of target-directed therapies in bladder cancer to
date is not necessarily a function of the lack of tractable drug targets
but rather the genomic heterogeneity of the disease. Until recently,
prospective characterization of individual patients was not feasible
because of technical and cost limitations. The findings presented here
underscore the need for prospective genomic characterization of pa-
tients with bladder cancer to enrich future clinical trials with patients
whose tumors harbor alterations in the drug target of interest.
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Fig 4. Alterations within the phosphoinositide 3-kinase (PI3K)/AKT pathway in high-grade bladder cancer. (A) Key components of the PI3K/AKT signaling pathway displayed
with their incidence of mutations and copy number abnormalities. The corresponding heatmap shows the distribution of pathway alterations across the tumor cohort. The
mRNA expression score for PTEN-deleted samples is shown to the right of the heatmap. P value comparing expression scores between samples harboring homozygous
deletion (homdel) versus diploid samples calculated by t test. (B) IC50 (concentration that inhibits 50%) values for a panel of urothelial cell lines with distinct PI3K/AKT pathway
alterations (as annotated) as well as one cell line with an HRAS mutation. Each cell line was exposed to increasing concentrations of MK2206 and harvested 5 days after
addition of drug. Cell viability was measured using trypan blue exclusion. (C) Immunoblot analysis of PI3K/AKT pathway downstream targets after exposure to MK2206 in the
MGH-U4 (PIK3CA H1047R) and the HCV-29 (TSC1 Q55*) cell lines. Cell were harvested at 0, 1, 6, and 24 hours after addition of drug. Hetloss, heterozygous loss.
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